Dermatology Trial Associates, Bryant, Arkansas, 72022, United States - 03 Nov `25Zasocitinib Tablets for Nonsegmental Vitiligo

Zasocitinib Tablets for Nonsegmental Vitiligo

Official title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

Status: Recruiting now

Description:

Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to...

Phase: Phase 2.

What is being studied: Drug: Zasocitinib; Other: Placebo.

Who can take part: ages 18 Years to 75 Years, 200 participants planned.

Enrollment status: Open now. The study starts 03 November 2025 and expected to finish 09 November 2027.

Contact: Takeda Contact, +1-877-825-3327, medinfoUS@takeda.com.

Source: ClinicalTrials.gov, NCT07108283 (https://clinicaltrials.gov/study/NCT07108283).

Start date: November 03, 2025

Completion date: November 09, 2027

Organizer: Takeda

Contact: Takeda Contact, +1-877-825-3327

Tel.: +1-877-825-3327

Email: medinfoUS@takeda.com

Link: https://clinicaltrials.gov/study/NCT07108283

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Zasocitinib Tablets for Nonsegmental Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Red Wine and Vitiligo

    Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...

  • Are there any famous people with vitiligo?

    Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...

  • Safety of clinical trials. Can my child leave it for any reason?

    Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...